Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Research & Development: 2014-2025

Historic Research & Development for ImmunityBio (IBRX) over the last 12 years, with Sep 2025 value amounting to $51.2 million.

  • ImmunityBio's Research & Development rose 1.56% to $51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $189.9 million, marking a year-over-year decrease of 8.01%. This contributed to the annual value of $190.1 million for FY2024, which is 18.17% down from last year.
  • As of Q3 2025, ImmunityBio's Research & Development stood at $51.2 million, which was down 7.25% from $55.2 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Research & Development registered a high of $79.3 million during Q1 2023, and its lowest value of $35.2 million during Q4 2024.
  • Moreover, its 3-year median value for Research & Development was $51.2 million (2025), whereas its average is $52.5 million.
  • In the last 5 years, ImmunityBio's Research & Development surged by 63.01% in 2021 and then crashed by 32.69% in 2024.
  • Over the past 5 years, ImmunityBio's Research & Development (Quarterly) stood at $51.8 million in 2021, then climbed by 12.22% to $58.1 million in 2022, then dropped by 11.27% to $51.5 million in 2023, then tumbled by 31.65% to $35.2 million in 2024, then grew by 1.56% to $51.2 million in 2025.
  • Its last three reported values are $51.2 million in Q3 2025, $55.2 million for Q2 2025, and $48.2 million during Q1 2025.